Entero Therapeutics Inc. (ENTO) Cash Flow Statement Analysis - Operating Cash Flow, CapEx & Free Cash Flow - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Entero Therapeutics Inc.

    NASDAQ: ENTO · Real-Time Price · USD
    3.13
    0.83 (36.09%)
    At close: Sep 12, 2025, 3:13 PM

    Entero Therapeutics Cash Flow Statement

    Financials in USD. Fiscal year is January - December.

    undefined peaked at n/a in undefined and hit its lowest at n/a in undefined. Over the past five years, it has declined by undefined%.

    Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
    Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
    Net Income
    		 -18.06M -15.79M -14.63M -58.54M
    Depreciation & Amortization
    		 48.95K 29.27K 29.27K 542.25K
    Stock-Based Compensation
    		 631.55K 1.04M 769.12K 1.37M
    Other Working Capital
    		 884.13K 2.26M -8.42K 15.13K
    Other Non-Cash Items
    		 5.63M 157.02K 277.43K 3.46M
    Deferred Income Tax
    		 n/a n/a n/a n/a
    Change in Working Capital
    		 2.53M 2.19M -10.5M 17.1M
    Operating Cash Flow
    		 -9.22M -12.38M -22.34M -32.29M
    Capital Expenditures
    		 n/a -500K n/a -10.32M
    Cash Acquisitions
    		 88.17K n/a n/a n/a
    Purchase of Investments
    		 n/a n/a n/a n/a
    Sales Maturities Of Investments
    		 n/a n/a n/a n/a
    Other Investing Acitivies
    		 n/a n/a n/a -10.25K
    Investing Cash Flow
    		 88.17K -500K n/a -10.32M
    Debt Repayment
    		 -644.58K -603.49K -641.24K 88.83K
    Common Stock Repurchased
    		 n/a n/a n/a n/a
    Dividend Paid
    		 n/a n/a n/a n/a
    Other Financial Acitivies
    		 45.00 657.00 -6.87M 4.91M
    Financial Cash Flow
    		 5.58M 15.23M 15.74M 44.76M
    Net Cash Flow
    		 -3.55M 2.35M -6.86M 2.19M
    Free Cash Flow
    		 -9.22M -12.88M -22.34M -42.61M

    Add to Watchlist